Abstract
Almost all tumors originating in the lymphatic cell system, except myelomas, are staged. The intensity and type of treatment is usually adapted to the stage of the disease. In more malignant or advanced stages, fairly intense combination chemotherapy is often used. In myelomas, treatment has often been less intense. Often a single cytostatic is used. Since myelomas are not usually staged, this is true even for advanced stages and malignant forms. However, staging procedures for myeloma have been proposed [4, 5]. For such a procedure to be clinically relevant, prognostic differences between the different stages have to be established. The present purpose was to study whether initial clinical parameters can be found which are correlated to the prognosis in myeloma. In addition, a differentiated program for treatment of the different stages is proposed, and some preliminary treatment results are reported.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alexanian, R., Haut, A., Khan, A. U., Lane, M., McKelvey, E. M., Migliore, P. J., Stickey, W. J., and Wilson, H. E.: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regiments. JAMA 208, 1680–1685 (1969)
Alexanian, R., Balcerzah, S., Bonnet, J. D., Gehan, E. A., Haut, A., Hewlett, J. S., and Monto, R. W.: Prognostic factors in multiple myeloma. Cancer 36, 1192–1201 (1975)
Arman, E., and Reizenstein, P.: Hand radioactivity after intravenous injection of 47Ca. Effect of age and femoral neck fracture. Geriatrics 26–165 (1971)
Durie, B. G. M., and Salmon, S. E.: A clinical staging system for multiple myeloma. Cancer 36, 842- 854 (1975)
Durie, B. G. M., and Salmon, S. E.: Cellular kinetics, staging, and immunoglobulin synthesis in multiple myeloma. Annu. Rev. Med. 26, 283–288 (1975)
Feinleib, M., and Mac Matron, B.: Duration of survival in multiple myeloma. J. Natl. Cancer Inst. 24, 1259–1269 (1960)
Galton, D. A. G., and Peto, R.: A progress report on the Medical Research Council’s therapeutic trial in myelomatosis. Br. J. Haematol. 15, 319–320 (1968)
Hobbs, J. R.: Growth rates and responses to treatment in human myelomatosis. Br. J. Haematol. 16, 607–617 (1969)
Hobbs, J. R.: Monitoring myelomatosis. Arch. Intern. Med. 135, 125–130 (1975)
Innes, J., and Newall, J.: Myelomatosis. Lancet I, 239–245 (1961)
Salmon, S. E.: Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 45, 119–129 (1975)
Sjöberg, H. E.: Retention of 47calcium administered orally in patients with primary hyperparathyroidism. Horm. Metab. Res. 2, 32–34 (1970)
Sjöberg, H. E., Reizenstein, P., and Arman, E.: Retention of orally administered 47Ca in man measured in a whole-body counter. Scand. J. Clin. Lab. Invest. 26, 67–71 (1970)
Waldenström, J.: Diagnosis and treatment of multiple myeloma. New York, London, Grune and Stratton (1970)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Ösby, E., Carlmark, B., Reizenstein, P. (1978). Staging of Myeloma. A Preliminary Study of Staging Factors and Treatment in Different Stages. In: Mathé, G., Seligmann, M., Tubiana, M. (eds) Lymphoid Neoplasias II. Recent Results in Cancer Research, vol 65. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81249-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-81249-1_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81251-4
Online ISBN: 978-3-642-81249-1
eBook Packages: Springer Book Archive